Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
March 11, 2024 07:00 ET
|
Pluri Inc.
HAIFA, Israel, March 11, 2024 (GLOBE NEWSWIRE) -- In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company") today...
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
March 06, 2024 07:00 ET
|
Pluri Inc.
HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote...
Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
February 28, 2024 07:00 ET
|
Pluri Inc.
Growing pipeline of industry-specific new potential products, services, collaborations and partnerships through PluriAgtech, PluriCDMO, PluriHealth, and PluriFoodRecent achievements include: new...
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
January 23, 2024 02:00 ET
|
Pluri Inc.
Pluri to leverage its proprietary 3D technology platform to develop cell-based products for the coffee industry under its new business vertical PluriAgtechThe rapidly growing $130 billion coffee...
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
January 08, 2024 07:00 ET
|
Pluri Inc.
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
December 21, 2023 07:00 ET
|
Pluri Inc.
Agreement signed following positive pre-clinical data demonstrating a one-time treatment with PLX-PAD significantly increased neurogenesis, offering immediate, long-term therapeutic effect in treating...
Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
August 16, 2023 07:00 ET
|
Pluri Inc.
Results support the development of PLX-R18 for hematologic acute radiation syndrome (H-ARS), currently under a $4.2 million contract with the U.S. National Institutes of HealthPLX-R18 has the...
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
July 13, 2023 02:00 ET
|
Pluri Inc.
HAIFA, Israel, July 13, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote...
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome
July 11, 2023 02:00 ET
|
Pluri Inc.
Pluri's cell therapy is designed to be the first in class, effective treatment for ionizing radiation poisoning in the event of a large-scale nuclear incident.The work specified by the contract is...
Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
April 27, 2023 07:00 ET
|
Pluri Inc.
Breakthrough system substantially increases cell production, with the potential to reach much higher productivity driven by platform’s significant scalability Flexible, industrial scale cell...